NCT01808313已完成3 期
An Open Label Phase IIIb Study to Evaluate Efficacy and Safety of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 134
- 试验地点
- 1
- 主要终点
- Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12
研究概览
简要总结
This open label, single-arm, non-controlled, multicentre study will determine the effect of ambrisentan on exercise capacity (6MWT) in Chinese subjects with PAH. The study consists of a screening period of 4 weeks, a 12-week primary evaluation period (PEP) and a 12-week dose-adjustment period (DAP). Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks (PEP).
详细描述
Pulmonary arterial hypertension (PAH) consists of a group of progressive and incurable diseases of the pulmonary vasculature. These are characterised by profound vasoconstriction and abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries, which leads to a progressive increase in pulmonary vascular resistance (PVR) and sustained elevations in pulmonary artery pressure (PAP). A variety of drug classes have been used to treat PAH but no single compound has yet been shown to be effective in treating all patients with the disease. Three widely used treatment options are calcium channel blockers (CCBs), diuretics and anticoagulants but all have varying responses.There is a lack of clinical data on ambrisentan among the Chinese population,Ambrisentan is conditionally approved for the treatment of PAH in China.A clinical trial with a minimum of 100 patients in the ambrisentan arm was requested by SFDA.Several PAH medications have been approved in China, so a placebo-controlled study is not ethically appropriate while an active control non-inferiority design is unfeasible due to sample size requirements and inconsistency in indications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent prior to beginning study-related procedures.
- •Subject must be between 18-75 years of age, inclusive, at the Screening Visit.
- •Subjects must weight ≥40 kg at the Screening Visit.
- •Subjects must have symptomatic or severe PAH (WHO functional class II or III) and be categorised as class 1 PAH (defined by the Updated Clinical Classification of Pulmonary Hypertension 2009), due to iPAH, congenital heart disease-congenital heart defects repaired greater than 1 year prior to screening (i.e., atrial septal defects, ventricular septal defects or patent ductus arteriosus) or CTD-related PAH (e.g., limited scleroderma, diffuse scleroderma, mixed CTD, systemic lupus erythematosus or overlap syndrome).
- •NOTE: subjects with portopulmonary hypertension and pulmonary venoocclusive disease are NOT eligible for the study.
- •Subjects must have had a right heart catheterisation within 6 months prior to screening and meet all of the following haemodynamic criteria:
- •Mean PAP ≥ 25 mmHg.
- •A PVR ≥ 240 dyn/sec/cm
- •A PCWP or left ventricular (LV) end-diastolic pressure of ≤ 15 mmHg.
- •Subjects must be able to walk a distance of at least 150 m but no more than 450 m. In addition, the screening and baseline 6MWT test values must not vary by greater than 10% (calculated using (baseline - screening)/screening with the result to be between -0.1 and 0.1).
- •Subjects must meet both of the following pulmonary function criteria. The tests should have been completed no more than 24 weeks prior to the Screening Visit, if not performed within the previous 24 weeks, the test must be completed at Day 0:
- •Total lung capacity (TLC) ≥ 60% of predicted normal.
- •Forced expiratory volume in one second (FEV1) ≥ 55% of predicted normal.
- •Subjects receiving CCBs must be on stable therapy (i.e., the dose level does not need to change to maintain disease control) for at least 1 month prior to the Screening Visit.
- •Subjects receiving 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (i.e., statins) must be on stable therapy (i.e., the dose level does not need to change to maintain disease control) for at least 12 weeks prior to the Screening Visit.
- •Female subjects of childbearing potential must have a negative pregnancy test at the Screening Visit and Day
- •Female subjects of childbearing potential who are sexually active must agree to use two reliable methods of contraception (as described in Appendix 3 ) from the Screening Visit until study completion and for at least 30 days following the last dose of IP. Subjects who have had a Copper T 380A intrauterine device (IUD) or LNg 20 IUD inserted are not required to use an additional method of contraception.
- •Subject must agree not to participate in a clinical study involving another IP or device throughout this study.
排除标准
- •The subject has received PAH therapy (PDE-5 inhibitors, ERA, chronic prostanoid*) within 4 weeks prior to the Screening Visit.
- •*Prostanoid use is classed as chronic when treatment continues for more than 7 days.
- •The subject has received intravenous inotropes (e.g., dopamine, dobutamine) within 2 weeks prior to the Screening Visit.
- •The subject has previously been discontinued from ERA treatment (e.g., bosentan) due to safety or tolerance issues other than those associated with liver function abnormalities.
- •The subject has a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value that is >2 x the upper limit of normal (ULN) at the Screening Visit.
- •The subject has serum bilirubin value that is >1.5 x ULN at the Screening Visit.
- •The subject has severe hepatic impairment (Child-Pugh class C with or without cirrhosis) at the Screening Visit.
- •The subject has severe renal impairment (creatinine clearance <30 mL/min) at the Screening Visit.
- •The subject has clinically significant anaemia, defined as haemoglobin concentration <10 g/dL or haematocrit <30% at the Screening Visit.
- •The subject has a laboratory result, physical examination finding, medical history incident or other finding, which is a contraindication for treatment with an ERA. Contraindications for treatment include, but are not limited to, evidence of elevated liver functions test or previously experiencing an event that would be defined as a serious AE (SAE) in a clinical trial (see Section 6.3.3.2), which was attributed to treatment with an ERA.
- •The subject has severe hypotension (either diastolic blood pressure <50 mmHg or systolic blood pressure <90 mmHg).
- •The subject has, in the opinion of the Investigator, clinically significant aortic or mitral valve disease, pericardial constriction, restrictive or congestive cardiomyopathy, life-threatening cardiac arrhythmias, significant LV dysfunction (defined as LV ejection fraction <45%), LV outflow obstruction, symptomatic coronary artery disease, autonomic hypotension or fluid depletion.
- •The subject has a history of malignancies within the past 5 years, with the exception of basal cell carcinoma of the skin or in situ carcinoma of the cervix.
- •The subject has cardiovascular, liver, renal, haematological, gastrointestinal, immunological, endocrine, metabolic or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject and/or efficacy of the study drug or severely limit the lifespan of the subject.
- •A female subject who is pregnant or breastfeeding.
- •The subject has demonstrated non-compliance with previous medical regimens or is unable to comply with the procedures described in this protocol.
- •The subject has a history of abusing alcohol or drugs of abuse (including amphetamines, methamphetamines, opiates, cannabinoids, cocaine, benzodiazepines or barbiturates) within 12 months prior to the Screening Visit. Use of such drugs if prescribed by a Doctor and used according to the prescription would not exclude a subject.
- •The subject has participated in a clinical study involving another IP or device within 4 weeks or five half-lives of an IP, whichever is longer, before the Screening Visit.
研究组 & 干预措施
ambrisentan
Experimental
ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
干预措施: ambrisentan (Drug)
结局指标
主要结局
Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12
时间窗: Baseline and Week 12
The 6MWT measures the distance that a participant can walk in a period of 6 minutes. Change from Baseline was calculated as the Week 12 value minus the Baseline value. Baseline 6MWT comprised of an average of the last two consecutive measurements prior to dosing that varied by not greater than 10 percent (%). If only one measurement was available, that measurement was used as the Baseline value. The last observation carried forward method was used to impute missing values.
次要结局
- Change From Baseline in 6MWT at Week 24(Baseline and Week 24)
- Number of Participants With a Change From Baseline in Their World Health Organization (WHO) Functional Classification (FC) at Weeks 12 and 24(Baseline, Week 12 and Week 24)
- Number of Participants With Any Adverse Events, Any Serious Adverse Events and Adverse Events Leading to Discontinuation(From the start of study treatment up to Week 24)
- Number of Participants With Physical Examination Findings(Baseline, Week 12 and Week 24)
- Change From Baseline in the Borg Dyspnea Index (BDI) at Weeks 12 and 24(Baseline, Week 12 and Week 24)
- Change From Baseline in the N-Terminal Pro-B-Type Natriuretic Peptide at Weeks 12 and 24(Baseline, Week 12 and Week 24)
- Number of Participants With the Indicated Event, as an Assessment of Time to Clinical Worsening of Pulmonary Arterial Hypertension (PAH) up to Week 24, Assessed as the First Occurrence of a Particular Event(Baseline up to Week 24)
- Change From Baseline in Electrocardiogram (ECG) Heart Rate Values at Weeks 12 and 24(Baseline, Week 12 and Week 24)
- Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Interval Corrected Bazett's Formula (QTcB) Values at Weeks 12 and 24(Baseline, Week 12 and Week 24)
- Change From Baseline in Systolic and Diastolic Blood Pressure at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Change From Baseline in Heart Rate at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Oral Temperature(Baseline)
- Number of Participants With Shift From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST) and Total Bilirubin (BILT) up to Week 24(Baseline up to Week 24)
- Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell (WBC) Count at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Change From Baseline in Hematocrit at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Change From Baseline in Mean Corpuscle Hemoglobin at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Change From Baseline in Albumin, Globulin and Total Protein at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Mean Change From Baseline in Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Change From Baseline in Calcium, Cholesterol, Chloride, Glucose, Potassium, Magnesium, Sodium, Inorganic Phosphorus, Triglycerides and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points up to Week 24(Baseline up to Week 24)
- Number of Participants With Urinalysis Data at Baseline and Week 24(Baseline and Week 24)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.Rheumatoid ArthritisNCT02011334Hoffmann-La Roche285
已完成
3 期
Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in ChinaParoxysmal Nocturnal HemoglobinuriaNCT05886244Alexion Pharmaceuticals, Inc.25
已完成
3 期
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT01941095Hoffmann-La Roche100
进行中（未招募）
3 期
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Locally Advanced or Metastatic Breast CancerNCT05296798Hoffmann-La Roche922
已完成
3 期
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.HER2-ve Metastatic Breast CancerGermline BRCA1/2 MutationsSomatic BRCA1/2 MutationsNCT03286842AstraZeneca256